Uma perspectiva chinesa sobre os fatores culturais a serem considerados pelo brasileiro no processo de negociação com o chinês

China emerges in the world as a potential economic leader and it is poised as the one of the strongest commercial partners of Brazil. China is already the third largest importer of Brazilian products and services and the prediction is to even increase that participation in the Brazilian export volume in the near future. As a consequence, there is a significant increase in commercial alliances between Brazilians and Chinese, which shows the need for the Brazilians to better understand the cultural differences when negotiating with the Chinese. The purpose of this research is to bring, from a Chinese point of view, the cultural difference in the negotiation process between Brazilians and Chinese. A better understanding of those differences will allow the Brazilians to adopt a better negotiation strategy with the Chinese in order to bring a better result. The research was developed by conducting 5 interviews with Chinese executives highly experienced in negotiation with the Brazilians. The results of this research show commons points indicated by the interviewers that have a direct impact on the negotiation process between Chinese and Brazilians.

Pharmaceutical patent bargains: the Brazilian experience

In the backdrop of the strict patent regime flatly adopted by the World Trade Organization (WTO) for all countries, a few countries constantly challenge this system through aggressive patent bargains. Within the pharmaceutical sector, noticeably, some countries now threaten to issue or otherwise actually issue compulsory licenses that may sway large pharmaceutical companies into selling drugs with large discounts or into granting voluntary licenses domestically. That is conspicuously the negotiation strategy adopted by Brazil in its negotiations with big international pharmaceutical companies.This paper explains Brazil’s aggressive bargaining approach based on an analysis of two aspects of its political economy. The first has to do with the international context of patent bargaining in the post-WTO era. Accordingly, the existence of large and fast growing domestic markets position countries such as Brazil as strategic destinations for Foreign Direct Investment (FDI) and trade. Together with an absence of a propensity to innovate in pharmaceutical products, these conditions boost Brazil’s bargaining power for issuing compulsory licenses over pharmaceutical products. The second aspect is related to political economy dynamics inside Brazil. Accordingly, the political framework in Brazil undermines long-term policies and favors short-sighted ones also vis-a-vis R&D investments in the pharmaceutical industry. This remains true regardless of the strictness of the patent regime in place. The lesson of Brazil is relevant arguably for other more powerful developing countries which presently examine Brazil's approach while further challenging the WTO's strict patent policy for the future.